MCID: RCR002
MIFTS: 32

Recurrent Hypersomnia

Categories: Mental diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Recurrent Hypersomnia

MalaCards integrated aliases for Recurrent Hypersomnia:

Name: Recurrent Hypersomnia 11 14
Disorders of Excessive Somnolence 43
Primary Recurrent Hypersomnia 11
Hypersomnia, Recurrent 71
Hypersomnia Recurrent 53

Classifications:



External Ids:

Disease Ontology 11 DOID:8619
ICD9CM 34 327.13
MeSH 43 D006970
SNOMED-CT 68 426451004
ICD10 31 G47.1
UMLS 71 C0751226

Summaries for Recurrent Hypersomnia

Disease Ontology: 11 A sleep disorder that involves recurring bouts of excessive amounts of sleepiness.

MalaCards based summary: Recurrent Hypersomnia, also known as disorders of excessive somnolence, is related to hypersomnia and idiopathic hypersomnia. An important gene associated with Recurrent Hypersomnia is HCRT (Hypocretin Neuropeptide Precursor), and among its related pathways/superpathways is Orexin and neuropeptides FF and QRFP bind to their respective receptors. The drugs Fluticasone and Selegiline have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and heart, and related phenotypes are nervous system and behavior/neurological

Related Diseases for Recurrent Hypersomnia

Diseases in the Hypersomnia family:

Recurrent Hypersomnia

Diseases related to Recurrent Hypersomnia via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 61, show less)
# Related Disease Score Top Affiliating Genes
1 hypersomnia 31.2 HLA-DQB1 HCRT
2 idiopathic hypersomnia 31.2 HLA-DQB1 HCRT
3 narcolepsy 1 30.2 P2RY11 HLA-DQB1 HCRT
4 rem sleep behavior disorder 29.9 IGLON5 HCRT
5 narcolepsy 29.3 P2RY11 HLA-DQB1 HCRTR2 HCRT
6 migraine with or without aura 1 29.2 HRH3 HCRTR2 HCRT
7 kleine-levin hibernation syndrome 29.1 TRANK1 TOR1B PNMA2 P2RY11 LMOD3 LGI1
8 sleep disorder 29.0 IGLON5 HRH3 HLA-DQB1 HCRTR2 HCRT
9 cranioectodermal dysplasia 10.4
10 narcolepsy 2 10.2 HLA-DQB1 HCRT
11 central sleep apnea 10.1 IGLON5 HCRT
12 autoimmune disease 10.1
13 oculodentodigital dysplasia 10.1
14 tatton-brown-rahman syndrome 10.1
15 guillain-barre syndrome 10.1 HLA-DQB1 HCRT
16 apnea, obstructive sleep 10.0 IGLON5 HCRT
17 sleep apnea 10.0
18 encephalopathy 10.0
19 postinfectious encephalitis 10.0 PNMA2 LGI1
20 akinetic mutism 10.0 PNMA2 LGI1
21 neurosarcoidosis 10.0 PNMA2 LGI1
22 gummatous syphilis 10.0 PNMA2 LGI1
23 chorea gravidarum 10.0 LGI1 IGLON5
24 meningovascular neurosyphilis 10.0 PNMA2 LGI1
25 miller fisher syndrome 10.0 PNMA2 LGI1
26 neuromuscular junction disease 10.0 PNMA2 LGI1
27 headache 10.0 HLA-DQB1 HCRTR2
28 autoimmune neuropathy 10.0 LGI1 IGLON5
29 advanced sleep phase syndrome 10.0 HCRTR2 HCRT
30 periodic limb movement disorder 10.0 HLA-DQB1 HCRTR2 HCRT
31 viral encephalitis 10.0 PNMA2 LGI1
32 demyelinating polyneuropathy 9.9 LGI1 IGLON5
33 anterograde amnesia 9.9 PNMA2 LGI1 HCRT
34 pervasive developmental disorder 9.9
35 autism spectrum disorder 9.9
36 migraine with aura 9.9
37 brain cancer 9.9
38 hepatic encephalopathy 9.9
39 endogenous depression 9.9
40 status epilepticus 9.9
41 post-traumatic stress disorder 9.9
42 bipolar disorder 9.9
43 mood disorder 9.9
44 migraine with brainstem aura 9.9
45 traumatic brain injury 9.9
46 rare pervasive developmental disorder 9.9
47 neuromyelitis optica 9.9 HLA-DQB1 HCRT
48 thymus gland disease 9.8 PNMA2 LGI1
49 autoimmune epilepsy 9.8 PNMA2 LGI1 IGLON5
50 la crosse encephalitis 9.8 PNMA2 LGI1 IGLON5
51 lingual-facial-buccal dyskinesia 9.8 PNMA2 LGI1 IGLON5
52 whipple disease 9.8 PNMA2 LGI1 IGLON5
53 mutism 9.8 PNMA2 LGI1 IGLON5
54 stiff-person syndrome 9.8 PNMA2 LGI1 IGLON5
55 limbic encephalitis 9.8 PNMA2 LGI1 IGLON5
56 autoimmune disease of peripheral nervous system 9.8 PNMA2 LGI1 IGLON5
57 choreatic disease 9.8 PNMA2 LGI1 IGLON5
58 thymus cancer 9.8 PNMA2 LGI1
59 hyperekplexia 9.8 PNMA2 LGI1 IGLON5
60 acute disseminated encephalomyelitis 9.7 PNMA2 LGI1 IGLON5 HCRT
61 von economo's disease 9.6 LGI1 IGLON5 HCRTR2 HCRT

Graphical network of the top 20 diseases related to Recurrent Hypersomnia:



Diseases related to Recurrent Hypersomnia

Symptoms & Phenotypes for Recurrent Hypersomnia

MGI Mouse Phenotypes related to Recurrent Hypersomnia:

45 (showing 2, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.5 HCRT HCRTR2 HLA-DQB1 HRH3 LGI1 LMOD3
2 behavior/neurological MP:0005386 9.23 HCRT HCRTR2 HLA-DQB1 HRH3 LGI1 LMOD3

Drugs & Therapeutics for Recurrent Hypersomnia

Drugs for Recurrent Hypersomnia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 72, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluticasone Approved, Experimental Phase 4 90566-53-3 4659387 5311101
2
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9, 14611-52-0 5195 26757
3
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
4 Hormones Phase 4
5 Psychotropic Drugs Phase 4
6 Antidepressive Agents Phase 4
7 Sympathomimetics Phase 4
8 Fluticasone-Salmeterol Drug Combination Phase 4
9 Bronchodilator Agents Phase 4
10 Adrenergic beta-Agonists Phase 4
11 Anti-Asthmatic Agents Phase 4
12 Adrenergic Agonists Phase 4
13 Anti-Allergic Agents Phase 4
14 Xhance Phase 4
15 Hormone Antagonists Phase 4
16 glucocorticoids Phase 4
17 Respiratory System Agents Phase 4
18 Anti-Inflammatory Agents Phase 4
19 Dermatologic Agents Phase 4
20
Salmeterol Xinafoate Phase 4 94749-08-3
21 Protective Agents Phase 4
22 Neuroprotective Agents Phase 4
23 Antiparkinson Agents Phase 4
24 Monoamine Oxidase Inhibitors Phase 4
25 Neurotransmitter Agents Phase 4
26 Nicotinic Agonists Phase 4
27 Cholinergic Agents Phase 4
28
Modafinil Approved, Investigational Phase 2, Phase 3 68693-11-8 4236
29
Methylphenidate Approved, Investigational Phase 2, Phase 3 113-45-1 4158
30
Dopamine Approved Phase 2, Phase 3 62-31-7, 51-61-6 681
31
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2 23431961
32
Sodium oxybate Approved Phase 3 502-85-2 23663870
33
Esreboxetine Approved, Experimental, Investigational Phase 3 98769-81-4, 71620-89-8, 98819-76-2 65856
34
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
35 Central Nervous System Stimulants Phase 2, Phase 3
36 Phosphodiesterase Inhibitors Phase 2, Phase 3
37 Dopamine Uptake Inhibitors Phase 2, Phase 3
38 Dopamine Agents Phase 2, Phase 3
39 Anesthetics, Intravenous Phase 2, Phase 3
40 Anesthetics, General Phase 2, Phase 3
41 Anesthetics Phase 2, Phase 3
42 Citrate Phase 2, Phase 3
43 Pharmaceutical Solutions Phase 3
44 Adrenergic Agents Phase 3
45
Flumazenil Approved Phase 1, Phase 2 78755-81-4 3373
46
Mirtazapine Approved Phase 2 85650-52-8, 61337-67-5 4205
47
Mazindol Approved, Investigational Phase 2 22232-71-9 4020
48
Flecainide Approved, Withdrawn Phase 2 54143-55-4 3356
49
Dextroamphetamine Approved, Illicit, Investigational Phase 2 51-64-9, 300-62-9 5826 3007
50
Clarithromycin Approved Phase 2 81103-11-9 84029
51
Pentetrazol Experimental, Withdrawn Phase 2 54-95-5
52 Convulsants Phase 2
53 Adrenergic Antagonists Phase 2
54 Adrenergic alpha-Antagonists Phase 2
55 Anti-Anxiety Agents Phase 2
56 Serotonin 5-HT3 Receptor Antagonists Phase 2
57 Histamine H1 Antagonists Phase 2
58 Histamine Antagonists Phase 2
59 Antidotes Phase 1, Phase 2
60 GABA Modulators Phase 1, Phase 2
61 Adderall Phase 2
62 Anti-Bacterial Agents Phase 2
63 Anti-Infective Agents Phase 2
64 Cytochrome P-450 Enzyme Inhibitors Phase 2
65 Cytochrome P-450 CYP3A Inhibitors Phase 2
66 Antibiotics, Antitubercular Phase 2
67
Serotonin Investigational, Nutraceutical Phase 2 50-67-9 5202
68
Caffeine Approved 58-08-2 2519
69
Benzocaine Approved, Investigational 1994-09-7, 94-09-7 2337
70
Tannic acid Approved 1401-55-4 16129878 16129778
71
Melatonin Approved, Nutraceutical, Vet_approved 73-31-4 896
72 Antioxidants

Interventional clinical trials:

(showing 127, show less)
# Name Status NCT ID Phase Drugs
1 The Efficacy and Tolerability of Modafinil for Fatigue and Daytime Sleepiness in Cancer Patients: Preliminary Study Unknown status NCT02385656 Phase 4 Modafinil
2 Double-Blind, Placebo-Controlled, Functional Neuroimaging Study of Armodafinil (200 mg/Day) on Prefrontal Cortical Activation in Patients With Residual Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Completed NCT00711516 Phase 4 Armodafinil;Placebo
3 Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study (SHARP): a 5-Week Double-blind, Placebo-controlled, Randomized, Crossover, Multicenter Study of Solriamfetol in Improving Cognitive Function in Participants With Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Plus Impaired Cognitive Function Completed NCT04789174 Phase 4 Solriamfetol;Placebo
4 TITLE: Double-blinded, Double-dummy, Study Comparing Fluticasone-salmeterol to Placebo in Patients With COPD and Associated Poor Sleep or Daytime Somnolence. Completed NCT00731770 Phase 4 Advair 250;Placebo- matched;Placebo;Advair 250 - matched
5 Effect of CPAP on Arterial Hypertension and Cardiovascular Morbi-Mortality in Patients With Sleep Apnea and Without Daytime Sleepiness Completed NCT00127348 Phase 4
6 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Armodafinil Treatment (150 mg) in Improving Clinical Condition Late in the Shift and in Improving Functional and Patient-Reported Outcomes in Adult Patients With Excessive Sleepiness Associated With Shift Work Disorder Completed NCT01080807 Phase 4 Armodafinil;Matching Placebo
7 A Multi-center, Open-Label Study to Evaluate the Efficacy and Safety of Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease Completed NCT04870372 Phase 4 Selegiline
8 A Phase 4, Open-Label, Single-Dose Study to Evaluate Sunosi® (Solriamfetol) Pharmacokinetics in Breast Milk and Plasma of Healthy Postpartum Women Following Oral Administration of Sunosi® Completed NCT05008341 Phase 4 Solriamfetol 150 mg Oral Tablet
9 Clinical Trial of Solriamfetol for Excessive Sleepiness Related to Shift Work Disorder Recruiting NCT04788953 Phase 4 Solriamfetol Oral Tablet;Placebo
10 Varenicline, a Partial Nicotinic Receptor Agonist for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease: a Placebo-controlled Cross-over Pilot Study Terminated NCT02473562 Phase 4 Varenicline;Placebo (for varenicline)
11 The Role of Palliative Care Interventions to Reduce Circadian Rhythm Disorders in Persons With Dementia: The Healthy Patterns Study Completed NCT03682185 Phase 3
12 A Double-blind, Randomized, Placebo Controlled, Two Arm Multi-center Study to Assess the Efficacy and Safety of a Once Nightly Formulation of Sodium Oxybate for Extended-Release Oral Suspension (FT218) for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Subjects With Narcolepsy Completed NCT02720744 Phase 3 FT218;Placebo
13 A 3-Day, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Armodafinil Treatment (50 and 150 mg/Day) in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder Completed NCT00758498 Phase 3 armodafinil;placebo
14 Caffeine for Excessive Daytime Somnolence in Parkinson's Disease Completed NCT00459420 Phase 2, Phase 3 Caffeine 100-200 mg BID;placebo
15 Efficacy and Safety of Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness Completed NCT02739568 Phase 3 Pitolisant (BF2.649);Placebo
16 A Randomised, Multicenter 12-Week Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson's Disease Followed by a 38 Week Open Label Extension Phase Completed NCT01066442 Phase 3 BF2.649 (Pitolisant)
17 Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multi-Center Trial Comparing the Effects of Orally Administered Xyrem (Sodium Oxybate) and Modafinil With Placebo in Treatment of Daytime Sleepiness in Narcolepsy Completed NCT00066170 Phase 3 Xyrem;Xyrem Placebo;Modafinil at established dose;Modafinil (Placebo)
18 Randomized, Double-blind, Placebo and Comparator-controlled, Parallel-group, Multi-center Trial Assessing the Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy Completed NCT01638403 Phase 3 BF2.649;Vigil;palcebo
19 BF2.649 in Patients With Obstructive Sleep Apnea Syndrome (OSA) and Treated by Nasal Continuous Positive Airway Pressure (nCPAP), But Still Complaining of Excessive Daytime Sleepiness (EDS) Completed NCT01071876 Phase 3 BF2.649;Placebo
20 Prospective, Randomized, Double-blind Study, Parallel-group, Multi-center Trial Assessing the Effects of Escalating Doses of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolepsy Completed NCT01067235 Phase 3 BF2.649;BF2.649 add on Modafinil
21 A Randomized, Multicenter 12-Week Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson's Disease Followed by a 38-Week Open-label Extension Phase Completed NCT01036139 Phase 3 BF2.649 (pitolisant)
22 Prospective, Randomized, Double-blind Study, Placebo-controlled, Parallel-group, Multi-center Trial Assessing the Effects of BF2.649 in Treatment of Excessive Daytime Sleepiness in Narcolepsy Completed NCT01067222 Phase 3 BF2.649;Modafinil;Placebo
23 A 12-Month, Open-Label, Flexible-Dosage (100 to 250 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil (CEP-10953) in the Treatment of Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder (With an Open-Ended Extension Period) Completed NCT00228553 Phase 3 Armodafinil 100 to 250 mg/day
24 A Short-term (8 Week) Open-Label Study, Followed by a Long Term Evaluation, to Assess Patient-Reported Outcomes With Armodafinil Treatment (150 to 250 mg/Day) for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome Completed NCT00228566 Phase 3 Armodafinil
25 A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension Completed NCT03533114 Phase 3 JZP-258;Placebo Oral Solution
26 A 12 Week, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CEP 10953 (150 mg) as Treatment for Adults With Excessive Sleepiness Associated With Chronic Shift Work Sleep Disorder Completed NCT00080288 Phase 3 Armodafinil 150 mg/day;Placebo
27 Efficacy and Safety of BF2.649 in Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea (OSA) Refusing the Nasal Continuous Positive Airway Pressure (nCPAP) Therapy Completed NCT01072968 Phase 3 BF2.649;Placebo
28 An Open-label Naturalistic Pragmatic Study to Assess the Long Term Safety of BF2.649 (Pitolisant) in the Treatment of Excessive Daytime Sleepiness (EDS) in Narcolepsy (12 Months Follow-up, Followed by a Prolonged Follow up) Completed NCT01399606 Phase 3 BF2.649
29 A Double-Blind, Placebo-Controlled, Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia Completed NCT02151253 Phase 2, Phase 3 Armodafinil;Placebo
30 A Randomized, Double Blind Study Comparing Pitolisant (BF2.649) to Placebo in Two Parallel Groups on the Weekly Frequency of Cataplexy Attacks and Excessive Daytime Sleepiness in Narcoleptic Patients With Cataplexy. Completed NCT01800045 Phase 3 Pitolisant;Placebo
31 Phase 2/3 Study of Efficacy and Tolerability of Methylphenidate in the Treatment of Excessive Daytime Sleepiness in Myotonic Dystrophy Type 1 Completed NCT01421992 Phase 2, Phase 3 Methylphenidate;Placebo
32 A Randomized, Double-Blind, Placebo-Controlled, Multi- Center Study to Assess the Efficacy and Safety of AXS-12 in the Treatment of Cataplexy and Excessive Daytime Sleepiness in Subjects With Narcolepsy Recruiting NCT05059223 Phase 3 AXS-12 (reboxetine);Placebo
33 A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia Recruiting NCT05156047 Phase 3 Pitolisant Oral Tablet;Placebo oral tablet
34 A Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Tolerance of Sodium Oxybate in Patients Affected With Idiopathic Hypersomnia Recruiting NCT03597555 Phase 2, Phase 3 Sodium Oxybate Oral Solution 500 MG/ML;Placebos
35 A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Pitolisant in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea Recruiting NCT05223166 Phase 3 Pitolisant;Placebo oral tablet
36 Open Label Study of Safety/Tolerability of Once Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy Patients That Have and Have Not Been Previously Maintained on Twice-nightly Sodium Oxybate IR Active, not recruiting NCT04451668 Phase 3 FT218
37 A Study to Assess the Long-term Efficacy and Safety of AXS-12 in the Treatment of Cataplexy and Excessive Daytime Sleepiness in Subjects With Narcolepsy Enrolling by invitation NCT05113745 Phase 3 AXS-12 (reboxetine);Placebo
38 An Open-Label Study to Evaluate the Long-Term Safety and Effectiveness of Pitolisant in Adult Patients With Idiopathic Hypersomnia Who Completed Study HBS-101-CL-010 Enrolling by invitation NCT05458128 Phase 3 pitolisant
39 Efficacy and Safety of Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness Withdrawn NCT02978651 Phase 3 Pitolisant (BF2.649);Placebo Oral Tablet
40 A Randomized, Placebo-Controlled, Double-Blind, Crossover Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia Unknown status NCT03542851 Phase 2 Pentetrazol (PTZ);Placebo oral capsule
41 A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Hypnotic Efficacy of EVT 201 in Elderly Patient With Daytime Sleepiness Completed NCT00401284 Phase 2 EVT 201
42 A Phase II, Eight Week, Multi-Center, Open Label Trial of Xyrem(R) (Sodium Oxybate) for Excessive Daytime Sleepiness and Nocturnal Sleep Disturbance in Patients With Mild to Moderate Parkinson's Disease Completed NCT00641186 Phase 2 sodium oxybate
43 A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multi-center Study of the Safety and Efficacy of ADX-N05 in the Treatment of Excessive Daytime Sleepiness in Subjects With Narcolepsy Completed NCT01681121 Phase 2 ADX-N05;Placebo
44 Randomized, Dose-finding Study of BF 2.649 5, 10 20 and 40 mg/d in Comparison to Placebo in Excessive Daytime Sleepiness in Parkinson's Disease Patients (PD) Completed NCT00642928 Phase 2 Placebo;BF 2.649 5 mg;BF 2.649 10 mg;BF 2.649 20 mg;BF 2.649 40 mg
45 A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness Completed NCT03037203 Phase 2 JZP-110
46 Antidepressant Response to a Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder Completed NCT00385437 Phase 2 Mirtazapine Treatment
47 A Four-week, Double-blind, Placebo-controlled, Randomized, Multicenter, Parallel-group Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in Adults for the Treatment of Narcolepsy Completed NCT04923594 Phase 2 mazindol extended release;Placebo
48 Dose Finding Phase IIb Study of Bavisant to Evaluate Its Safety and effiCacy in treAtment of exceSsive Daytime sleePiness (EDS) in PARkinson's Disease (PD). Completed NCT03194217 Phase 2 BEN-2001;Placebo
49 Clarithromycin for the Treatment of Hypersomnia Completed NCT01146600 Phase 2 Clarithromycin followed by placebo;Placebo then Clarithromycin
50 Minimum Effective Dose-Finding Study of BF2.649, in Patients With Moderate to Severe OSA, Experiencing EDS Despite Regular Use of nCPAP, and Patients Having Refused This Therapy - Randomized, Double Blind Study With BF2.649 or Placebo Completed NCT01620554 Phase 2 BF2.649;Placebo
51 A Randomized, Double-Blind, Placebo-Controlled, Crossover On-Road Driving Study Assessing the Effect of JZP-110 on Driving Performance in Subjects With Excessive Sleepiness Due to Narcolepsy Completed NCT02806908 Phase 2 JZP-110;Placebo
52 A Randomized Phase 2, Double Blind, Placebo-Controlled, Multi-Center Crossover Study Of PF-03654746 As A Daily Treatment For Excessive Daytime Sleepiness (EDS) Associated With Narcolepsy Completed NCT01006122 Phase 2 Placebo;PF-03654746
53 A Randomized, Double-Blind, Placebo-Controlled, Crossover On-Road Driving Study Assessing the Effect of JZP-110 on Driving Performance in Subjects With Excessive Sleepiness Due to Obstructive Sleep Apnea Completed NCT02806895 Phase 2 JZP-110;Placebo
54 Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness Completed NCT03624920 Phase 2 THN102 Dosage A;THN102 Dosage B;THN102 Dosage C
55 A Randomized, Placebo-Controlled, Double-blind, Fixed-Dose, Multiple Cohort, Multiple Crossover, Dose-Finding Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2 Completed NCT02512588 Phase 2 BTD-001;Placebo
56 A Ten Subject, Double-Blind, Placebo-Controlled Trial of Single Day Dosing of Sublingual Flumazenil in Individuals With Primary Hypersomnia or Excessively Long Total Sleep Time and Excess Endogenous Potentiation of GABA-A Receptors Completed NCT01183312 Phase 1, Phase 2 Flumazenil
57 A Four-week, Double-blind, Placebo-controlled, Randomized, Cross-over Study of the Safety and Efficacy of ADX-N05 in the Treatment of Excessive Daytime Sleepiness Completed NCT01485770 Phase 2 ADX-N05;Placebo
58 Informing Treatment Decisions in the Central Disorders of Hypersomnolence: A Pragmatic Clinical Trial of Modafinil Versus Amphetamines Recruiting NCT03772314 Phase 2 Modafinil;Amphetamine-Dextroamphetamine
59 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1, Followed by an Open-Label Extension Recruiting NCT04886518 Phase 2 Pitolisant Oral Tablet;Placebo oral tablet
60 Antibiotic-mediated Improvements in Vigilance: Mechanisms of Action of Clarithromycin in Hypersomnia Syndromes Recruiting NCT04026958 Phase 2 Clarithromycin;Placebo
61 A Double-blind, Randomized, Placebo-controlled, Parallel, Study to Assess the Efficacy and Safety of XW10172 MR for the Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease Not yet recruiting NCT05056194 Phase 2 Valiloxybate
62 Phase IIa, Randomized, Double-blind, Placebo-controlled, 3-period Crossover, Adaptive Dose Design, Clinical Trial to Evaluate Safety & Efficacy of MK0249 in Treating Refractory Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea/Hypopnea Syndrome Appropriately Using nCPAP Therapy. Terminated NCT00620659 Phase 2 Comparator: MK0249;Comparator: placebo;Comparator: modafinil
63 A Randomized, Phase II Placebo-controlled Study of the Use of Extended-release Methylphenidate or Modafinil for the Treatment of Excessive Daytime Sleepiness in Children Following Cancer Therapy Terminated NCT01348607 Phase 2 methylphenidate hydrochloride;modafinil;placebo
64 A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Crossover Study of a Single Intravenous Infusion Dose of TAK-925 in Patients With Idiopathic Hypersomnia Completed NCT04091438 Phase 1 TAK-925;TAK-925 Placebo
65 A Phase 1b Randomized, Double-blind, Placebo-Controlled, Crossover Study of 2 Single Intravenous Infusion Doses of TAK-925 in Subjects With Obstructive Sleep Apnea Who Are Experiencing Excessive Daytime Sleepiness Despite Adequate Use of CPAP Completed NCT04091425 Phase 1 TAK-925;Placebo
66 A Multiple Dose Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of ABT-652 Administered Once Daily to Subjects With an Excessive Daytime Sleepiness Disorder Completed NCT01124851 Phase 1 ABT-652;Placebo
67 A Double-Blind, Phase 1, Single-Center, Single-Ascending Dose Study of JZP-386 Compared to Xyrem® vs. Placebo to Evaluate the Safety and Pharmacokinetics Completed NCT02215499 Phase 1 Placebo;Sodium Oxybate;JZP-386
68 Is the Daytime Sleepiness Based on Epworth Sleepiness Scale a Good Way to Assess Taiwanese With Suspected Obstructive Sleep Apnea. Unknown status NCT04631783
69 Prevalence and Characteristics of Sleep Disturbances Among Psychiatric Inpatients Unknown status NCT04201392
70 Effects of Telemedicine and Humidification for Continous Positive Airway Pressure (CPAP) in OSAS. Unknown status NCT04300166
71 Hypersomnia in Major Depressive Disorder Unknown status NCT04006834
72 Comparison Between the Situational and the Time-of-day Recording of Daytime Sleepiness in Patients With the Assessment of a Sleep-related Respiratory Disorder Unknown status NCT04448470
73 Behavior of Psychomotor Vigilance Task Performance in Subjects With Obstructive Sleep Apnea With and Without Complaints of Daytime Sleepiness Unknown status NCT01562262
74 A Randomized Controlled Trial of Effects From a Mandibular Advancement Device in Patients With Obstructive Sleep Apnea and Snoring Completed NCT00477009
75 Sleep-Disordered Breathing and CPAP After Adenotonsillectomy in Children Completed NCT01554527
76 Improving the Assessment of Hypersomnolence Completed NCT02884505
77 Evaluation of Excessive Diurnal Sleepiness by the Expression and Activity of Salivary Amylase in Children With Hypersomnia. Completed NCT01926405
78 Psychosocial Adjunctive Treatment for Hypersomnia (PATH): A Pilot Trial Completed NCT03904238
79 Symptomatic Endometriosis of the Posterior Cul-de-sac is Associated With Impaired Sleep Quality, Excessive Daytime Sleepiness and Insomnia: a Case-control Study. Completed NCT02027142
80 An Eight Week, Double-Blind, Placebo Controlled, Adjunctive Study of the Primary Effects of the Use of Flexible Doses of Modafinil 50mg to 200mg, on the Negative Symptoms, Cognition, and Excessive Daytime Sleepiness in Schizophrenic Patients Completed NCT00546403 Modafinil;Placebo
81 The CPAP Effect in Severe Obstructive- Sleep- Apnea Patients Without Daytime Sleepiness: A Control Randomized Trial Completed NCT00491088
82 Sustainable Methods, Algorithms, and Research Tools for Delivering Optimal Care Study (SMART DOCS) Completed NCT02037438
83 Community-Level Daytime Sleepiness: Social-Environmental Determinants, Consequences, and Impact of Sleep Apnea Completed NCT04176042
84 Assessing the Effect of the MYODM Food Supplement on Quality of Life, Fatigue and Hypersomnia in Patients With Myotonic Dystrophy Type 1 Completed NCT04634682
85 Population-bases Study to Asses Prevalence of Sleep Disorders and Their Association With Cardiovascular Risk Factors and Diseases Completed NCT01877616
86 Differential Diagnosis and Management of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea: A Modified Delphi Consensus Panel Report Completed NCT05055271
87 The Role of the Circadian System in Neurological Sleep-wake Disorders: Assessment of Circadian and Homeostatic Sleep-wake Regulation and Vigilance With a Poly-nap Protocol Completed NCT03356938
88 The Feasibility of a Tailored Music Intervention to Reduce Symptoms of Sleep Disruption in Older Adults With Dementia Completed NCT04157244
89 A Placebo Control, Double Blind, Cross Over Study of Modafinil in Patients With Narcolepsy Completed NCT00174174 Modafinil
90 Anesthetic Management of Patients With Chronic Sleep Disorders Completed NCT04827329
91 The Effect of Acupressure on the Sleep Quality and Daytime Sleepiness of Surgical Nurses During the COVID-19 Pandemic Process Completed NCT04800939
92 Effect of Strength Training on the Quality and Duration of Sleep and Daytime Sleepiness of Institutionalized Adolescents: A Randomized Study Completed NCT03110731
93 Training Protocol for Various Sleep Disorders in Patients With Neurological Disorders Completed NCT00001664
94 Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies, Impact of Modafinil Treatment. Completed NCT00916253 Modafinil;Placebo
95 Diagnostic Validity Study and Cost Analysis of Domiciliary Respiratory Completed NCT00614952
96 Importance of Sleep Deprivation in Differential Diagnosis of Primary Hypersomnia in Reference Centers Rare Hypersomnia Completed NCT03459300
97 Cardiovascular Variability and Heart Rate Arousal Response in Idiopathic Hypersomnia Completed NCT02913651
98 The Effects of Mindfulness on Disrupted Sleep in Bipolar Disorder Completed NCT01764035
99 Neurophysiologic Correlates of Hypersomnia: a High Density EEG Investigation Completed NCT01719315
100 Cognitive Assessment in Excessive Daytime Sleepiness: Electrophysiological Study. Completed NCT03446066
101 Effects of Litebook EDGE™ Phototherapy on Academic Performance and Functional Brain Activity in Non-Depressed Adolescents Completed NCT05383690
102 Feasibility of Detecting Within Subject Differences in Sleepiness With NextSense Earbud Electroencephalography Devices Recruiting NCT05066009
103 Swiss Primary Hypersomnolence and Narcolepsy Cohort Study Recruiting NCT04330963
104 Analysis of New Salivary Biomarkers to Evaluate Excessive Diurnal Sleepiness in Children With Hypersomnia Recruiting NCT05183464
105 Constitution of a Clinical, Neurophysiological and Biological Cohort for Chronic Sleep Disorders Responsible of Hypersomnolence Recruiting NCT03998020
106 Voice Biomarkers to Predict Excessive Daytime Sleepiness Recruiting NCT04942574
107 Study on Disease Course and Quality of Life in Patients With Sleep Disorders (Mainz Sleep Registry) Recruiting NCT05321355
108 The Effect of Lifestyle Modifications on Aspects Related to Fatigue, Quality of Life, Health, and Sleepiness in Professional Drivers Recruiting NCT05096130
109 Coordination of Rare Diseases at Sanford Recruiting NCT01793168
110 Integral Physiological Adaptations to Carbohydrate Periodization Recruiting NCT05464342
111 A Multi-Signal Based Monitoring System for CNS Hypersomnias : A 10-year Longitudinal Study Recruiting NCT05443373
112 Validating the Use of a Novel Subjectively Reported Sleep Vital Sign for the Identification and Management of Sleep Disorders Active, not recruiting NCT03018912
113 Idiopathic Hypersomnia - a Retrospective Characterization Study Enrolling by invitation NCT05150977
114 Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments Enrolling by invitation NCT05371483
115 Multiple Reaction Monitoring (MRM) Versus I 125 Radioimmunoassay (RIA) for the Quantification of Orexin-A/Hypocretin-1 Levels in Cerebrospinal Fluid: a Prospective Diagnostic Validation Study in Patients With Hypersomnolence Not yet recruiting NCT05615584
116 Feasibility Study of Utilizing At-Home Electroencephalography Monitoring for Diagnosing and Treatment Monitoring of Hypersomnia Not yet recruiting NCT05627388
117 Randomized Control Trial to Compare Patient Outcomes Following Unattended Polysomnography Versus In-lab Polysomnography for Sleep Apnea and Comorbid Sleep Disorders Not yet recruiting NCT05230394
118 An Open Label Expanded Access Program Intended to Provide Treatment With HBS-101 (Pitolisant) to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy No longer available NCT03433131 Pitolisant
119 Disrupted Sleep in the Elderly: Light Exposure Studies Suspended NCT00427323
120 'A Profile of Physical Performance Variables in an Out-patient Adult Population With Narcolepsy' Suspended NCT04419792
121 Use of CPAP to Reduce Arterial Stiffness in Moderate to Severe Obstructive Sleep Apnea, Without Excessive Daytime Sleepiness (STIFFSLEEP) Terminated NCT02273089
122 Transcranial Direct Current Stimulation Therapy for Central Hypersomnia Without Cataplexy Terminated NCT03198156
123 Melatonin for Circadian Sleep Disorders in the Blind Terminated NCT00911053 Melatonin
124 Effect of a Structured Physical Activity Program on Sleep Quality and Sleepiness in Parkinson's Disease Terminated NCT01544465
125 Comparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease Withdrawn NCT00393562 modafinil;methylphenidate
126 Open-label Clinical Trial to Evaluate the Efficacy of Sodium Oxybate (Xyrem®) in the Treatment of Two Under-recognized Clinical Conditions: Post-traumatic Narcolepsy and Post-traumatic Hypersomnia Withdrawn NCT03626727 Early Phase 1 Sodium Oxybate Oral Solution [Xyrem]
127 STaRtS: Start Times and Restful Sleep Withdrawn NCT04049682

Search NIH Clinical Center for Recurrent Hypersomnia

Cochrane evidence based reviews: disorders of excessive somnolence

Genetic Tests for Recurrent Hypersomnia

Anatomical Context for Recurrent Hypersomnia

Organs/tissues related to Recurrent Hypersomnia:

MalaCards : Brain, Breast, Heart, Thalamus

Publications for Recurrent Hypersomnia

Articles related to Recurrent Hypersomnia:

(showing 51, show less)
# Title Authors PMID Year
1
A patient with anti-aquaporin 4 antibody who presented with recurrent hypersomnia, reduced orexin (hypocretin) level, and symmetrical hypothalamic lesions. 53 62
18226957 2009
2
Different circadian rest-active rhythms in Kleine-Levin syndrome: a prospective and case-control study. 62
33851710 2021
3
[Tularaemia in two patients referred on suspicion of cancer mammae and cancer occulta]. 62
33000721 2020
4
Usefulness of brain SPECT imaging in the study of recurrent hypersomnia: Kleine-Levin syndrome. 62
28869046 2019
5
Kleine-Levin syndrome: A neuropsychiatric disorder. 62
29606318 2018
6
Recurrent Hypersomnia and Autonomic Dysregulation in Posttraumatic Stress Disorder. 62
29117891 2017
7
A Case of Recurrent Hypersomnia With Autonomic Dysfunction. 62
28633719 2017
8
Migraine with brainstem aura presenting as recurrent hypersomnia (Kleine-Levin syndrome). 62
27343267 2016
9
Kleine-Levin Syndrome. 62
27137943 2016
10
Recurrent hypersomnia in an 18-year old boy: CSF hypocretin level and MSLT findings. 62
26323648 2016
11
Do the Symptoms of Kleine-Levin Syndrome Correlate With the Hypometabolism of the Thalamus on FDG PET? 62
26562572 2016
12
Menstruation-Related Hypersomnia Treated with Hormonal Contraception: Case Report and Review of Literature. 62
26932284 2016
13
Circadian disruption: New clinical perspective of disease pathology and basis for chronotherapeutic intervention. 62
27308960 2016
14
Recurrent hypersomnia: Report of medication-responsive cases. 62
26483951 2015
15
Narcolepsy with and without cataplexy, idiopathic hypersomnia with and without long sleep time: a cluster analysis. 62
25576137 2015
16
Misdiagnosis of menstruation-related recurrent hypersomnia as epilepsy in a patient with generalized epileptic discharges. 62
25878739 2015
17
Treatment of Kleine-Levin syndrome with acetazolamide. 62
25317098 2014
18
Kleine-Levin syndrome: a case report and review of literature. 62
24630285 2014
19
Kleine-Levin syndrome: a review. 62
24470783 2014
20
[The Kleine-Levin syndrome: new aspects of a rare disease]. 62
23942582 2013
21
Recurrent hypersomnia following traumatic brain injury. 62
23499199 2013
22
Diagnosis and management of central hypersomnias. 62
22973425 2012
23
Recurrent hypersomnia due to occult hepatic encephalopathy. 62
22154356 2012
24
A rapid screening test for depression in junior high school children. 62
21872817 2011
25
Recurrent hypersomnia: a review of 339 cases. 62
20970360 2011
26
Familial recurrent hypersomnia: two siblings with Kleine-Levin syndrome and menstrual-related hypersomnia. 62
20404354 2010
27
[A case of recurrent hypersomnia with excellent response to lithium carbonate]. 62
21061548 2010
28
Non-convulsive status epilepticus presenting as recurrent hypersomnia. 62
20463123 2010
29
Gabapentin for Kleine-Levin syndrome. 62
19571456 2009
30
Polysomnography in Kleine-Levin syndrome. 62
18316691 2008
31
Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. 62
18246980 2007
32
Hypersomnias of central origin. 62
16963696 2006
33
Differential diagnosis in hypersomnia. 62
16522270 2006
34
Hypersomnia. 62
16416710 2005
35
Case study: differences in human Per2 gene expression, body temperature, cortisol, and melatonin parameters in remission and hypersomnia in a patient with recurrent hypersomnia. 62
14535361 2003
36
[Recurrent hypersomnia]. 62
14503208 2003
37
Decreased blood flow of the left thalamus during somnolent episodes in a case of recurrent hypersomnia. 62
12047594 2002
38
Recurrent hyper- and hyposomnia: a new diagnostic entity? Polysomnographic findings and a 30-year follow-up. 62
14592248 2002
39
[Disorders of awakening. Second part: secondary disorders]. 62
11438768 2001
40
Kleine Levin syndrome (KLS) in young females. 62
10875563 2000
41
Prolonged polysomnography in a case with recurrent hypersomnia. 62
9628153 1998
42
[Recurrent hypersomnia]. 62
9503836 1998
43
Recurrent hypersomina: a case report with polysomnographic findings. 62
11847365 1997
44
Treatment of recurrent hypersomnia with methylcobalamin (vitamin B12): a case report. 62
8726119 1995
45
Electrophysiological and immunogenetic findings in recurrent monosymptomatic-type hypersomnia: a study of two unrelated Italian cases. 62
8256576 1993
46
Recurrent hypersomnia in two adolescent males with Asperger's syndrome. 62
1644738 1992
47
[Recurrent hypersomnia caused by acute toluene poisoning]. 62
2361041 1990
48
[Recurrent hypersomnia]. 62
3047832 1988
49
Recurrent hypersomnia secondary to sleep apnea. 62
718480 1978
50
Recurrent hypersomnia secondary to sleep apnea. 62
889488 1977
51
[Kleine-Levin syndrome (recurrent hypersomnia of male adolescents]. 62
5559004 1971

Variations for Recurrent Hypersomnia

Expression for Recurrent Hypersomnia

Search GEO for disease gene expression data for Recurrent Hypersomnia.

Pathways for Recurrent Hypersomnia

Pathways related to Recurrent Hypersomnia according to GeneCards Suite gene sharing:

(showing 1, show less)
# Super pathways Score Top Affiliating Genes
1 9.53 HCRTR2 HCRT

GO Terms for Recurrent Hypersomnia

Biological processes related to Recurrent Hypersomnia according to GeneCards Suite gene sharing:

(showing 2, show less)
# Name GO ID Score Top Affiliating Genes
1 feeding behavior GO:0007631 9.13 HCRTR2 HCRT
2 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.1 P2RY11 HCRTR2 HCRT

Sources for Recurrent Hypersomnia

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....